

IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

FORMATION OF THE AUDIT AND RISK COMMITTEE AND RECONSTITUTION OF THE BOARD COMMITTEES

The Board of Directors (the “**Board**”) of iX Biopharma Ltd (the “**Company**”) wishes to announce that with immediate effect, the Audit Committee and the Risk Management Committee of the Company be merged to form the “Audit and Risk Committee”. The formation of the Audit and Risk Committee shall streamline the roles and responsibilities of the Board committee members.

The Board also refers to its announcement dated 1 October 2024 in relation to the retirement of Ms Angeline Tham as an Independent Director of the Company upon the conclusion of the Annual General Meeting held on 17 October 2024 and wishes to announce that the Board Committees of the Company be reconstituted as follows with immediate effect:

Audit and Risk Committee

Teo Woon Keng John Chairperson
Patrick Donald Davies Member
Albert Ho Shing Tung Member

Nominating Committee

Patrick Donald Davies Chairperson
Teo Woon Keng John Member
Eddy Lee Yip Hang Member

Remuneration Committee

Patrick Donald Davies Chairperson
Albert Ho Shing Tung Member
Teo Woon Keng John Member

By Order of the Board

Gwendolin Lee Soo Fern/
Lai Kuan Loong, Victor
Company Secretaries

17 October 2024

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.